Skip to main content

PRODUCTION UNIT FOR THE DECENTRALISED ENGINEERING OF AUTOLOGOUS CELL-BASED OSTEOINDUCTIVE BONE SUBSTITUTES

Objective

Bone is among the most frequently transplanted tissues and autography account for the majority of bone graft procedures. However, auto grafts always require a secondary surgery adding high costs to health services increase patient morbidity and are available in very limited quantities. Therefore, there is widespread interest around the world for programmes to rebuild and restore function of degenerative tissue using artificial implant materials. The enormous need for bone grafts and the recent progresses in biomedical and biomaterial sciences have stimulated the rapid growth and expansion of a new field: bone tissue engineering. However, this approach presents important limits to the transfer from an academic to a routine clinical environment: high cost, difficulties in transferring biological samples between hospitals and centralized "cell factories"; reproducibility due to lack of standards. The aim of this project is to combine the developments in the areas of tissue engineering based on materials and 3D scaffolds development with largely laboratory and few commercial activities in the field of bioreactors and transpose the concepts of tissue engineering and regeneration of the frontiers of new developments: the automated production of antilogous bone replacement materials The goal of this project is to develop a bioreactor that would be set-up within the confines oaf hospital and which would be used to homogenously activate specially designed porous matrices with stem cells from harvested bone marrow aspirates of the patient to produce antilogous hybrid bone graftmaterials.This target will be achieved through the following scientific and technical objectives:
1) design and production of innovative bioreactors,
2) design and production of novel biomaterials and scaffolds architectures tailored for both bioreactor use and bone tissue engineering,
3) validation of the approach in preclinical animal studies.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /engineering and technology/industrial biotechnology/biomaterials
  • /engineering and technology/environmental biotechnology/bioremediation/bioreactor
  • /medical and health sciences/medical biotechnology/implants
  • /medical and health sciences/medical biotechnology/tissue engineering

Call for proposal

FP6-2002-NMP-1
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

CONSIGLIO NAZIONALE DELLE RICERCHE
Address
Piazzale Aldo Moro 7
Roma
Italy

Participants (11)

DANSK TEKNOLOGISK INSTITUT
Denmark
Address
Gregersensvej
Taastrup
FIN-CERAMICA FAENZA S.R.L.
Italy
Address
Via Granarolo 102
Faenza
FUNDACION TEKNIKER
Spain
Address
Avenida Otaola 20
Eibar
INSTITUT NATIONAL POLYTECHNIQUE DE TOULOUSE
France
Address
Allee Emile Monso, 6
Toulouse
JOHANNES GUTENBERG UNIVERSITAET MAINZ
Germany
Address
Saarstrasse 21
Mainz
LABORATOIRE D'EVALUATION DES MATERIELS IMPLANTABLES SA
France
Address
Technopole Montesquieu
Martillac
MILLENIUM BIOLOGIX AG
Switzerland
Address
Wagistrasse 23
Schlieren-zurich
ODENSE UNIVERSITETSHOSPITAL
Denmark
Address
Sdr. Boulevard 29
Odense
PRESENS PRECISION SENSING GMBH
Germany
Address
Josef Engert Strasse 9
Regensburg
UNIVERSITA DEGLI STUDI DI GENOVA
Italy
Address
Via Balbi 5
Genova
UNIVERSITAET BASEL
Switzerland
Address
Petersplatz 1
Basel